Healthcare
Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided
Oslo, 26 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. This concludes the previously communicated wrap-up phase of th
About this update from Zelluna Asa
Oslo, 26 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. This concludes the previously communicated wrap-up phase of the UV1 cancer vaccine programme and Zelluna now considers the programme closed. Highlights: Background and results The DOVACC trial tested the cancer vaccine UV1 in patients with BRCAwt platinum sensitive recurrent ovarian cancer. The goal was to assess whether UV1, given alongside two established cancer medicines, could slow disease progression better than standard treatment alone. The DOVACC readout represents the fifth Phase II study evaluating UV1 that has not met its primary endpoint. About Zelluna ASA Zelluna ASA (OSE: ZLNA) is a pioneering allogeneic 'off-the-shelf' T Cell Receptor-based Natural Killer (TCR-NK) cells for the treatment of solid cancers. The company's platform combines the innate killing power of NK cells with precise solid tumour targeting of TCRs, designed to address the limitations of current cell therapies in solid tumours. The company's lead candidate, ZI-MA4-1, is the world's first MAGE-A4 targeting TCR-NK therapy in clinical testing. Zelluna is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway and is listed on the Euronext Oslo Stock Exchange under the ticker ZLNA. For further information, please visit www.zelluna.com or contact: Namir Hassan, CEOEmail: [email protected]: +44 7720 687608